The impact of age on risk assessment, therapeutic practice and outcome in candidemia

References

• Diekema DJ, Arbefeville S, Boyken L. The changing epidemiology of health-care associated candidemia over three decades. Diagn Microbiol Infect Dis. 2012;73:45–48.
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev. 2007;20:133–163.
   PubMed Web of Science ®Google Scholar
• Gudlaugsson O, Gillespie S, Lee K. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis. 2003;37:1172–1177.
   PubMed Web of Science ®Google Scholar
• Pappas PG, Kauffman CA, Andes D, et al. Infectious Diseases Society of America: clinical practice guidelines for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62:1–50.
   PubMed Web of Science ®Google Scholar
• Tissot F, Agrawal S, Pagano L, et al. ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients. Haematologica. 2017;102:433–444.
   PubMed Web of Science ®Google Scholar
• Ullmann AJ, Akova M, Herbrecht R, et al. ESCMID guideline for the diagnosis and the management of Candida diseases 2012: adult with haematological malignancies and after haematopoietic stem cell transplantation (HCT). Clin Microbiol Infect. 2012;18:53–67.
   PubMed Web of Science ®Google Scholar
• Cornely OA, Bassetti M, Calandra T, et al. ESCMID guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect. 2012;18:19–37.
   PubMed Web of Science ®Google Scholar
• Baran J, Muckatira B, Khatib R. Candidemia before and during the fluconazole era: prevalence, type of species and approach to treatment in a tertiary care community hospital. Scand J Infect Dis. 2001;33:137–139.
   PubMedGoogle Scholar
• Guinea J. Global trends in the distribution of Candida species causing candidemia. Clin Microbiol Infect. 2014;20:5–10.
   Web of Science ®Google Scholar
• Wang H, Liu N, Yin M. The epidemiology, antifungal use and risk factors of death in elderly patients with candidemia: a multicenter retrospective study. BMC Infect Dis. 2014;14:609–617.
   PubMed Web of Science ®Google Scholar
• Eggimann P, Garbino J, Pittet D. Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet Infect Dis. 2003;3:685–702.
   PubMed Web of Science ®Google Scholar
• Cornely OA, Gachot B, Akan H, et al. Epidemiology and outcome of fungemia in a cancer cohort of the infectious disease group (IDG) of the European Organization for research and treatment of cancer (EORTC 65031). Clin Infect Dis. 2015;61:324–331.
   PubMed Web of Science ®Google Scholar
• Li C, Wang H, Yin M, et al. The difference in epidemiology and predictors of death between candidemia acquired in intensive care units and other hospital settings. Intern Med. 2015;54:3009–3016.
   PubMed Web of Science ®Google Scholar
• Bassetti M, Righi E, Ansaldi F, et al. A multicenter study of septic shock due to candidaemia: outcomes and predictors of mortality. Intensive Care Med. 2014;40:839–845.
   PubMed Web of Science ®Google Scholar
• Tascini C, Sozio E, Tintori G, et al. Peripherally inserted central catheter as a predominant risk factor for candidemia in critically ill patients in Internal Medicine wards in Italy. Int Care Med. 2015;41:1498–1499.
   PubMed Web of Science ®Google Scholar
• Leroy O, Gangneux JP, Montravers P, et al. Epidemiology, management, and risk factors for death of Candida infections in critical care: a multicentre, prospective, observational study in France (2005–2006). Crit Care Med. 2009;37:1612–1618.
   PubMed Web of Science ®Google Scholar
• Garnacho-Montero J, Diaz-Martin A, Garcia-Gabrera E, et al. Impact on hospital mortality of catheter removal and adequate antifungal therapy in Candida spp. blood stream infections. J Antimicrob Chemother. 2013;68:206–213.
   PubMed Web of Science ®Google Scholar
• Asmundsdóttir LR, Erlendsdóttir H, Gottfredsson M. Improving survival of patients with candidaemia: analysis of prognostic factors from a long-term, nationwide study in Iceland. Scand J Infect Dis. 2005;37:111–120.
   PubMed Web of Science ®Google Scholar
• Morell M, Fraser V, Kollef MH. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother. 2005;49:3640–3645.
   PubMed Web of Science ®Google Scholar
• Hesstvedt L, Gaustad P, Andersen CT, et al. Twenty-two years of candidaemia surveillance: results from a Norwegian national study. Clin Microbiol Infect. 2015;21:938–945.
   PubMed Web of Science ®Google Scholar
• Sandven P, Bevanger L, Digranes A, et al. Candidemia in Norway (1991 to 2003): Results from a nationwide study. J Clin Microbiol. 2006;44:1991–2003.
   Web of Science ®Google Scholar
• Sandven P, Bevanger L, Digranes A, et al. Constant low rate of fungemia in Norway, 1991 to 1996. The Norwegian Yeast Study Group. J Clin Microbiol. 1998;36:3455–3459.
   PubMed Web of Science ®Google Scholar
• NORM/NORM-VET 2015. Usage of antimicrobial agents and occurrence of antimicrobial resistance in Norway. Tromsø/Oslo 2016. ISSN: 1502-2307 (print)/1890-9965 (electronic).
   Google Scholar
• Arendrup MC, Sulim S, Holm A, et al. Diagnostic issues, clinical characteristics, and outcomes for patients with fungemia. J Clin Microbiol. 2011;49:3300–3308.
   PubMed Web of Science ®Google Scholar
• Bassetti M, Merelli M, Righi E, et al. Epidemiology, species distribution, antifungal susceptibility, and outcome of Candidemia across five sites in Italy and Spain. J Clin Microbiol. 2013;51:4167–4172.
   PubMed Web of Science ®Google Scholar
• Wisplinghoff H, Ebbers J, Geurtz L, et al. Nosocomial bloodstream infections due to Candida spp. in the USA: species distribution, clinical features and antifungal susceptibilities. Int J Antimicrob Agents. 2014;43:78–81.
   PubMed Web of Science ®Google Scholar
• Barchiesi F, Orsetti E, Mazzanti S, et al. Candidemia in the elderly: what does it change?. Plos One. 2017;12:e0176576.
   PubMed Web of Science ®Google Scholar
• Kauffman CA. Fungal infections in older adults. Clin Infect Dis. 2001;33:550–555.
   PubMed Web of Science ®Google Scholar
• Guimares T, Nucci M, Mendonca J, et al. Epidemiology and predictors of a poor outcome in elderly patients with candidaemia. Int J Infect Dis. 2012;16:442–447.
   Web of Science ®Google Scholar
• Ghannoum MA, Jurevic RJ, Mukherjee PK, et al. Characterization of the oral fungal microbiome (Mycobiome) in healthy individuals. PLoS Pathog. 2010;6:e1000713.
   PubMed Web of Science ®Google Scholar
• Falcone M, Tiseo G, Tascini C, et al. Assessment of risk factors for candidemia in non-neutropenic patients hospitalized in Internal Medicine wards: a multicenter study. Eur J Int Med. 2017;41:33–38.
   PubMed Web of Science ®Google Scholar
• Puig-Asensio M, Ruiz-Camps I, Fernandez-Ruis M, et al. Epidemiology and outcome of candidemia in patients with oncological and hematological malignancies: results from a population-based surveillance in Spain. Clin Microbiol Infect. 2015;21:491.e2.
   Google Scholar
• Lortholary O, Renaudat C, Sitbon K, et al. The risk and clinical outcome of candidemia depending on underlying malignancy. Intensive Care Med. 2017;43:652–662.
   PubMed Web of Science ®Google Scholar
• Pfaller M, Neofytos D, Diekema D, et al. Epidemiology and outcomes of candidemia in 3648 patients: data from the prospective antifungal therapy registry, 2004–2008. Diagn Microbiol Infect Dis. 2012;74:323–331.
   PubMed Web of Science ®Google Scholar
• Kollef M, Micek S, Hampton M, et al. Septic shock attributed to Candida infection: importance of empiric therapy and source control. Clin Infect Dis. 2012; 54:1739–1746.
   PubMed Web of Science ®Google Scholar
• Skrobik Y, Laverdiere M. Why Candida sepsis should matter to ICU physicians. Crit Care Clin. 2013;29:853–864.
   PubMed Web of Science ®Google Scholar
• Andes DR, Safdar N, Baddley JW, et al. Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. Clin Infect Dis. 2012;54:1110–1120.
   PubMed Web of Science ®Google Scholar
• Murri R, Scoppettuolo G, Ventura G, et al. Initial antifungal strategy does not correlate with mortality in patients with candidemia. Eur J Clin Microbiol Infect Dis. 2016; 35:187–193.
   PubMed Web of Science ®Google Scholar
• Dekkers BGJ, Veringa A, Marriott DJE, et al. Invasive candidiasis in the elderly: considerations for drug therapy. Drugs and Drugs Aging. 2018;35:781–789.
   PubMed Web of Science ®Google Scholar
• Lausch KR, Søgaard M, Rosenvinge FS, et al. Treatment of candidaemia in a nationwide setting: increased survival with primary echinocandin treatment. Infect Drug Resist. 2018;11:2449–2459.
   PubMed Web of Science ®Google Scholar
• Tascini C, Falcone M, Bassetti M, et al. Candidemia in patients with body temperature below 37 °C and admitted to Internal Medicine wards: assessment of risk factors. Am J Med. 2016;129:1330.e1–1330e6.
   Web of Science ®Google Scholar
• Berdal JE, Haagensen R, Ranheim T, et al. Nosocomial candidemia; risk factors and prognosis revisited; 11-year experience from a Norwegian Secondary Hospital. PLoS One. 2014;9:e103916.
   PubMed Web of Science ®Google Scholar